Matches in SemOpenAlex for { <https://semopenalex.org/work/W4256271194> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W4256271194 endingPage "151" @default.
- W4256271194 startingPage "143" @default.
- W4256271194 abstract "Objective: Medication-assisted treatment for substance use disorders (SUDs) is not widely used in treatment programs. The aims of the current study were to document the prevalence of adoption and implementation of extended-release injectable naltrexone, the newest U.S. Food and Drug Administration–approved medication for alcohol use disorder (AUD), in U.S. treatment programs and to examine associations between organizational and patient characteristics and adoption. Method: The study used interview data from a nationally representative sample of 307 U.S. SUD treatment programs to examine adoption and implementation of injectable naltrexone. Results: Thirteen percent of programs used injectable naltrexone for AUD, and 3% of programs used it for opioid use disorder. Every treatment program that offered injectable naltrexone to its patients used it in conjunction with psychosocial treatment, particularly cognitive behavioral therapy. Multivariate logistic regression results indicated that adoption was positively associated with the provision of wraparound services, the percentage of privately insured patients, and the presence of inpatient detoxification services. For-profit status and offering inpatient services were negatively associated with adoption. Within adopting programs, an average of 4.1% of AUD patients and 7.1% of patients with opioid use disorder were currently receiving the medication, despite clinical directors’ reports of positive patient outcomes, particularly for relapsers and for those who had been noncompliant with other medications. Cost was a significant issue for the majority of adopting organizations. Conclusions: The rate of adoption of injectable naltrexone in U.S. treatment programs remains limited. Researchers should continue to examine patient, organizational, and external characteristics associated with the adoption and implementation of injectable naltrexone over time." @default.
- W4256271194 created "2022-05-12" @default.
- W4256271194 creator A5050599495 @default.
- W4256271194 creator A5076259158 @default.
- W4256271194 creator A5085578813 @default.
- W4256271194 date "2015-01-01" @default.
- W4256271194 modified "2023-09-30" @default.
- W4256271194 title "Adoption of Injectable Naltrexone in U.S. Substance Use Disorder Treatment Programs" @default.
- W4256271194 doi "https://doi.org/10.15288/jsad.76.1.143" @default.
- W4256271194 hasPublicationYear "2015" @default.
- W4256271194 type Work @default.
- W4256271194 citedByCount "1" @default.
- W4256271194 countsByYear W42562711942019 @default.
- W4256271194 crossrefType "journal-article" @default.
- W4256271194 hasAuthorship W4256271194A5050599495 @default.
- W4256271194 hasAuthorship W4256271194A5076259158 @default.
- W4256271194 hasAuthorship W4256271194A5085578813 @default.
- W4256271194 hasConcept C118552586 @default.
- W4256271194 hasConcept C126322002 @default.
- W4256271194 hasConcept C150966472 @default.
- W4256271194 hasConcept C151956035 @default.
- W4256271194 hasConcept C170493617 @default.
- W4256271194 hasConcept C185592680 @default.
- W4256271194 hasConcept C2777972943 @default.
- W4256271194 hasConcept C2779418921 @default.
- W4256271194 hasConcept C2779436514 @default.
- W4256271194 hasConcept C2779442783 @default.
- W4256271194 hasConcept C2781063702 @default.
- W4256271194 hasConcept C2781066024 @default.
- W4256271194 hasConcept C40010229 @default.
- W4256271194 hasConcept C512399662 @default.
- W4256271194 hasConcept C55493867 @default.
- W4256271194 hasConcept C71924100 @default.
- W4256271194 hasConceptScore W4256271194C118552586 @default.
- W4256271194 hasConceptScore W4256271194C126322002 @default.
- W4256271194 hasConceptScore W4256271194C150966472 @default.
- W4256271194 hasConceptScore W4256271194C151956035 @default.
- W4256271194 hasConceptScore W4256271194C170493617 @default.
- W4256271194 hasConceptScore W4256271194C185592680 @default.
- W4256271194 hasConceptScore W4256271194C2777972943 @default.
- W4256271194 hasConceptScore W4256271194C2779418921 @default.
- W4256271194 hasConceptScore W4256271194C2779436514 @default.
- W4256271194 hasConceptScore W4256271194C2779442783 @default.
- W4256271194 hasConceptScore W4256271194C2781063702 @default.
- W4256271194 hasConceptScore W4256271194C2781066024 @default.
- W4256271194 hasConceptScore W4256271194C40010229 @default.
- W4256271194 hasConceptScore W4256271194C512399662 @default.
- W4256271194 hasConceptScore W4256271194C55493867 @default.
- W4256271194 hasConceptScore W4256271194C71924100 @default.
- W4256271194 hasIssue "1" @default.
- W4256271194 hasLocation W42562711941 @default.
- W4256271194 hasOpenAccess W4256271194 @default.
- W4256271194 hasPrimaryLocation W42562711941 @default.
- W4256271194 hasRelatedWork W2006819528 @default.
- W4256271194 hasRelatedWork W2052813313 @default.
- W4256271194 hasRelatedWork W2057185756 @default.
- W4256271194 hasRelatedWork W2074009448 @default.
- W4256271194 hasRelatedWork W2098572450 @default.
- W4256271194 hasRelatedWork W2123703357 @default.
- W4256271194 hasRelatedWork W2597120360 @default.
- W4256271194 hasRelatedWork W2777612558 @default.
- W4256271194 hasRelatedWork W3048146082 @default.
- W4256271194 hasRelatedWork W3174377162 @default.
- W4256271194 hasVolume "76" @default.
- W4256271194 isParatext "false" @default.
- W4256271194 isRetracted "false" @default.
- W4256271194 workType "article" @default.